Serina Therapeutics, Inc. (NYSEAMERICAN:SER – Get Free Report) saw a significant decline in short interest in the month of September. As of September 30th, there was short interest totaling 56,600 shares, a decline of 52.6% from the September 15th total of 119,360 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average trading volume of 121,092 shares, the days-to-cover ratio is currently 0.5 days.
Serina Therapeutics Price Performance
Shares of SER stock traded up $0.08 during trading hours on Thursday, reaching $1.79. The company’s stock had a trading volume of 27,435 shares, compared to its average volume of 1,481,298. The company has a quick ratio of 6.65, a current ratio of 6.65 and a debt-to-equity ratio of 0.16. Serina Therapeutics has a fifty-two week low of $1.22 and a fifty-two week high of $5.29. The company has a market capitalization of $45.47 million, a price-to-earnings ratio of -0.95 and a beta of 1.19. The firm’s 50 day simple moving average is $2.37 and its 200-day simple moving average is $2.09.
Serina Therapeutics (NYSEAMERICAN:SER – Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.55) earnings per share for the quarter.
Wall Street Analysts Forecast Growth
Separately, BTIG Research reiterated a “buy” rating and issued a $8.00 price target on shares of Serina Therapeutics in a research report on Thursday, September 10th. One investment analyst has rated the stock with a Buy rating. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $8.00.
View Our Latest Analysis on SER
Serina Therapeutics Company Profile
Serina Therapeutics, Inc is a clinical-stage biotechnology company developing medicines designed to provide controlled and sustained drug delivery. The company’s proprietary POZ polymer platform is intended to extend the duration of action of therapeutic compounds, potentially reducing dosing frequency and improving treatment convenience.
Serina’s lead product candidate is SER-252, also known as POZ-apomorphine, an investigational long-acting formulation of apomorphine being developed for patients with Parkinson’s disease.
Read More
- Five stocks we like better than Serina Therapeutics
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Receive News & Ratings for Serina Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Serina Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
